top of page




Mice overexpressing Bcl-2 in their neurons are resistant to myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE).

Offen D, Kaye JF, Bernard O, Merims D, Coire CI, Panet H, Melamed E, Ben-Nun A.

J Mol Neurosci. 2000 Dec;15(3):167-76.

Haloperidol-induced neurotoxicity--possible implications for tardive dyskinesia.

Galili R, Mosberg, Gil-Ad I, Weizman A, Melamed E, Offen D.

J Neural Transm (Vienna). 2000;107(4):479-90.

The molecular mechanism of dopamine-induced apoptosis: identification and characterization of genes that mediate dopamine toxicity.

Barzilai A, Zilkha-Falb R, Daily D, Stern N, Offen D, Ziv I, Melamed E, Shirvan A.

J Neural Transm Suppl. 2000;(60):59-76.

Apoptosis as a general cell death pathway in neurodegenerative diseases.

Offen D, Elkon H, Melamed E.

J Neural Transm Suppl. 2000;(58):153-66. Review.

Levodopa--an exotoxin or a therapeutic drug?

Melamed E, Offen D, Shirvan A, Ziv I.

J Neurol. 2000 Apr;247 Suppl 2:II135-9. Review.


Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.

Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I.

Brain Res. 2000 Jan 31;854(1-2):257-62.

Developmental changes in antioxidant enzymes and oxidative damage in kidneys, liver and brain of bcl-2 knockout mice.

Hochman A, Liang H, Offen D, Melamed E, Sternin H.

Cell Mol Biol (Noisy-le-grand). 2000 Feb;46(1):41-52.


Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis.

Offen D, Hochman A, Gorodin S, Ziv I, Shirvan A, Barzilai A, Melamed E.

Adv Neurol. 1999;80:265-9. Review.

The involvement of p53 in dopamine-induced apoptosis of cerebellar granule neurons and leukemic cells overexpressing p53.

Daily D, Barzilai A, Offen D, Kamsler A, Melamed E, Ziv I.

Cell Mol Neurobiol. 1999 Apr;19(2):261-76.


Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease.

Offen D, Gorodin S, Melamed E, Hanania J, Malik Z.

Neurosci Lett. 1999 Jan 29;260(2):101-4.



Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels.

Offen D, Halevi S, Orion D, Mosberg R, Stern-Goldberg H, Melamed E, Atlas D.

Neurology. 1998 Oct;51(4):1100-3.


Levodopa toxicity and apoptosis.

Melamed E, Offen D, Shirvan A, Djaldetti R, Barzilai A, Ziv I.

Ann Neurol. 1998 Sep;44(3 Suppl 1):S149-54. Review.


Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice.

Hochman A, Sternin H, Gorodin S, Korsmeyer S, Ziv I, Melamed E, Offen D.

J Neurochem. 1998 Aug;71(2):741-8.

HTLV-1 in mouthwash cells from a TSP/HAM patient and asymptomatic carriers.

Offen D, Achiron A, Wasserman L, Miller M, Shaklai M, Dabby R, Gorodin S, Shohat B.

Arch Virol. 1998;143(5):1029-34.


Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity.

Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, Gorodin S, Melamed E, Bernard R, Bernard O.

Proc Natl Acad Sci U S A. 1998 May 12;95(10):5789-94.



Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease.

Offen D, Ziv I, Barzilai A, Gorodin S, Glater E, Hochman A, Melamed E.

Neurochem Int. 1997 Aug;31(2):207-16.

Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bcl-2.

Offen D, Ziv I, Panet H, Wasserman L, Stein R, Melamed E, Barzilai A.

Cell Mol Neurobiol. 1997 Jun;17(3):289-304.


Monoamine-induced apoptotic neuronal cell death.

Zilkha-Falb R, Ziv I, Nardi N, Offen D, Melamed E, Barzilai A.

Cell Mol Neurobiol. 1997 Feb;17(1):101-18.


The proto-oncogene Bcl-2 inhibits cellular toxicity of dopamine: possible implications for Parkinson's disease.

Ziv I, Offen D, Haviv R, Stein R, Panet H, Zilkha-Falb R, Shirvan A, Barzilai A, Melamed E.

Apoptosis. 1997;2(2):149-55.


Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease?

Ziv I, Offen D, Barzilai A, Haviv R, Stein R, Zilkha-Falb R, Shirvan A, Melamed E.

J Neural Transm Suppl. 1997;49:195-202. Review.


Nigrostriatal neuronal death in Parkinson's disease--a passive or an active genetically-controlled process?

Ziv I, Barzilai A, Offen D, Nardi N, Melamed E.

J Neural Transm Suppl. 1997;49:69-76. Review.


Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?

Ziv I, Zilkha-Falb R, Offen D, Shirvan A, Barzilai A, Melamed E.

Mov Disord. 1997 Jan;12(1):17-23.



Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease.

Offen D, Ziv I, Sternin H, Melamed E, Hochman A.

Exp Neurol. 1996 Sep;141(1):32-9.


Detection of proviral human T-cell lymphotrophic virus type I DNA in mouthwash samples of HAM/TSP patients and HTLV-I carriers.

Achiron A, Pinhas-Hamiel O, Barak Y, Doll L, Offen D, Djaldetti R, Frankel G, Shohat B.

Arch Virol. 1996;141(1):147-53.


Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease?

Ziv I, Barzilai A, Offen D, Stein R, Achiron A, Melamed E.

Adv Neurol. 1996;69:229-33. Review.



Dopamine-induced programmed cell death in mouse thymocytes.

Offen D, Ziv I, Gorodin S, Barzilai A, Malik Z, Melamed E.

Biochim Biophys Acta. 1995 Aug 31;1268(2):171-7.


Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons--a possible novel pathogenetic mechanism in Parkinson's disease.

Ziv I, Melamed E, Nardi N, Luria D, Achiron A, Offen D, Barzilai A.

Neurosci Lett. 1994 Mar 28;170(1):136-40.



Induction of tolerance to an IgG autoantibody.

Offen D, Spatz L, Escowitz H, Factor S, Diamond B.

Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8332-6.


Possible involvement of (2'5')oligoadenylate synthetase activity in pre-mRNA splicing.

Sperling J, Chebath J, Arad-Dann H, Offen D, Spann P, Lehrer R, Goldblatt D, Jolles B, Sperling R.

Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10377-81.

A novel splicing factor is an integral component of 200S large nuclear ribonucleoprotein (InRNP) particles.

Ast G, Goldblatt D, Offen D, Sperling J, Sperling R.

EMBO J. 1991 Feb;10(2):425-32.


Monoclonal anti-La antibody derived from a mouse with experimental SLE is similar to human anti-La antibodies.

Offen D, Mendlovic S, Fricke H, Sperling R, Sperling J, Mozes E.

J Autoimmun. 1990 Dec;3(6):701-13.

Pathogenic anti-DNA antibodies in SLE: idiotypic families and genetic origins.

Paul E, Manheimer-Lory A, Livneh A, Solomon A, Aranow C, Ghossein C, Shefner R, Offen D, Pillinger M, Diamond B.

Int Rev Immunol. 1990;5(3-4):295-313. Review.

Identification of nuclear RNP proteins as pre-mRNA splicing factors.

Ast G, Offen D, Goldblatt D, Sperling R, Sperling J.

Mol Biol Rep. 1990;14(2-3):193. 

Induction of experimental systemic lupus erythematosus in mice by immunization with a monoclonal anti-La autoantibody.

Fricke H, Offen D, Mendlovic S, Shoenfeld Y, Bakimer R, Sperling J, Mozes E.

Int Immunol. 1990;2(3):225-30.


Autoantibodies against a specific nuclear RNP protein in sera of patients with autoimmune rheumatic diseases associated with myositis.

Arad-Dann H, Isenberg DA, Shoenfeld Y, Offen D, Sperling J, Sperling R.

J Immunol. 1987 Apr 15;138(8):2463-8.


U1, U2, and U6 small nuclear ribonucleoproteins (snRNPs) are associated with large nuclear RNP particles containing transcripts of an amplified gene in vivo.

Sperling R, Spann P, Offen D, Sperling J.

Proc Natl Acad Sci U S A. 1986 Sep;83(18):6721-5.



bottom of page